Bristol Myers Squibb Expands AI Collaboration with Nvidia
Bristol Myers Squibb (NYSE: BMY) has announced an expanded partnership with Nvidia (NASDAQ: NVDA) to enhance its drug discovery process using artificial intelligence (AI). This collaboration includes the deployment of a next-generation DGX SuperPOD AI supercomputer, aimed at building a more powerful AI drug discovery platform. The move is part of Bristol Myers’ ongoing strategy to speed up the development of new medicines and reduce costs in an industry known for its slow and expensive processes.
The investment in Nvidia’s technology comes at a pivotal time as Bristol Myers faces significant challenges from patent cliffs on key products like Eliquis and Opdivo. With a strong pipeline featuring promising candidates such as next-gen anticoagulant milvexian and cancer drug pumitamig, the company is focused on offsetting potential revenue losses from generics. Bristol Myers’ stock is currently trading at 9.7 times forward earnings, below the healthcare sector average of 18.1 times, marking potential buying opportunities as the company integrates AI to improve efficiency.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
